Humor and Quirks Humor and Quirks
Wed, December 11, 2024
Tue, December 10, 2024
[ Tue, Dec 10th 2024 ] - The New Yorker
The Dawn of the Bionic Man
[ Tue, Dec 10th 2024 ] - Mercury News
California News
[ Tue, Dec 10th 2024 ] - ABC News
Entertainment News
Mon, December 9, 2024
[ Mon, Dec 09th 2024 ] - BBC
Beds, Herts & Bucks
[ Mon, Dec 09th 2024 ] - Uproxx
The Best TV Shows Of 2024
[ Mon, Dec 09th 2024 ] - Paste
The 25 Best PC Games of 2024
[ Mon, Dec 09th 2024 ] - CNET
Top News Stories
Sun, December 8, 2024
Sat, December 7, 2024
[ Sat, Dec 07th 2024 ] - Newsweek
Russia-Ukraine War
[ Sat, Dec 07th 2024 ] - imdb.com
Canada's 30 Funniest TV Shows
[ Sat, Dec 07th 2024 ] - Daily Mail
UK Celebrity News
[ Sat, Dec 07th 2024 ] - Food Safety News
Food Safety News
Fri, December 6, 2024
[ Fri, Dec 06th 2024 ] - Graphic
Latest Ghana News Headlines Today
[ Fri, Dec 06th 2024 ] - The Columbian
Clark County News
[ Fri, Dec 06th 2024 ] - who13
Cyclones react to 10 wins
[ Fri, Dec 06th 2024 ] - TravelPulse
Hotels and Resorts News
[ Fri, Dec 06th 2024 ] - Business Standard
Share Market Today
[ Fri, Dec 06th 2024 ] - Reuters
Aerospace & Defense
Thu, December 5, 2024
[ Thu, Dec 05th 2024 ] - Interest
All news stories
[ Thu, Dec 05th 2024 ] - Stereogum
When Comedians Make Serious Music
[ Thu, Dec 05th 2024 ] - Paste
The 30 Best TV Shows of 2024
[ Thu, Dec 05th 2024 ] - Phil Bruner
Featured News Stories
[ Thu, Dec 05th 2024 ] - Phil Bruner
Swattie Survival Guide
Wed, December 4, 2024
[ Wed, Dec 04th 2024 ] - Phil Bruner
California News
[ Wed, Dec 04th 2024 ] - Phil Bruner
President Joe Biden
Tue, December 3, 2024
[ Tue, Dec 03rd 2024 ] - Phil Bruner
The 40 Best Games of 2024
[ Tue, Dec 03rd 2024 ] - Phil Bruner
Boku No Roblox Codes
[ Tue, Dec 03rd 2024 ] - Phil Bruner
Yonhap News Agency
[ Tue, Dec 03rd 2024 ] - Phil Bruner
Beds, Herts & Bucks
[ Tue, Dec 03rd 2024 ] - Phil Bruner
Transfer news and rumors
Mon, December 2, 2024
[ Mon, Dec 02nd 2024 ] - Phil Bruner
Watch Samaa News Live
[ Mon, Dec 02nd 2024 ] - Phil Bruner
UK Celebrity News
[ Mon, Dec 02nd 2024 ] - Phil Bruner
The 100 Best Albums of 2024
[ Mon, Dec 02nd 2024 ] - Phil Bruner
From the Newspaper
[ Mon, Dec 02nd 2024 ] - Phil Bruner
South Australia
[ Mon, Dec 02nd 2024 ] - Phil Bruner
Whanganui Chronicle
Sun, December 1, 2024
[ Sun, Dec 01st 2024 ] - Phil Bruner
Wildlife Oddities of the Week
Sat, November 30, 2024
Fri, November 29, 2024
[ Fri, Nov 29th 2024 ] - Phil Bruner
Hotels and Resorts News
[ Fri, Nov 29th 2024 ] - Phil Bruner
The Best Jokes of 2024
Thu, November 28, 2024
[ Thu, Nov 28th 2024 ] - Phil Bruner
Climate and Environment
[ Thu, Nov 28th 2024 ] - Phil Bruner
December 2024 Issue
Wed, November 27, 2024
[ Wed, Nov 27th 2024 ] - Phil Bruner
Decoding Gen Z's content diet
Tue, November 26, 2024
[ Tue, Nov 26th 2024 ] - Phil Bruner
Illustrated Humor in the News
[ Tue, Nov 26th 2024 ] - Phil Bruner
World News
[ Tue, Nov 26th 2024 ] - Phil Bruner
Alexandra Petri
Mon, November 25, 2024
[ Mon, Nov 25th 2024 ] - Phil Bruner
Legal IT's Leading News Source
[ Mon, Nov 25th 2024 ] - Phil Bruner
All Kent news
Sun, November 24, 2024
Mon, December 15, 2008
[ Mon, Dec 15th 2008 ] - Market Wire
fasdfasddva s gfg h

Sirona Biochem's Skin Lightener Compound Seven Times More Effective Than Popular Commercial Lightener in Study


//health-fitness.news-articles.net/content/2012/ .. -than-popular-commercial-lightener-in-study.html
Published in Health and Fitness on Thursday, November 15th 2012 at 13:17 GMT by Market Wire   Print publication without navigation


November 15, 2012 16:05 ET

Sirona Biochem's Skin Lightener Compound Seven Times More Effective Than Popular Commercial Lightener in Study

Compound viability in $9 billion market established; Product development takes next steps

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Nov. 15, 2012) - Sirona Biochem Corp (TSX VENTURE:SBM) today reported that its skin depigmenting agent, TFC-723, reduced melanin production seven times more effectively than beta arbutin, a leading skin lightener. The study, funded through a $1.9 million French government grant, is led by Sirona Biochem's subsidiary company TFChem and includes a consortium of partners.

"The use of cosmetic skin lighteners is increasing dramatically worldwide and we plan to meet the demand for a more effective and safer skin lightening agent," said Neil Belenkie, Chief Executive Officer of Sirona Biochem. "We are thrilled that these positive study results continue to reinforce the benefits of our proprietary platform over existing technologies," Mr. Belenkie added.

Efficacy studies were conducted using commercial human tyrosinase Feldan® to determine the compound's ability to inhibit tyrosinase activity. Tyrosinase is an enzyme responsible for melanin production or darkening of the skin. In the study, TFC-723 inhibited melanin production more effectively than commercial skin lightener beta arbutin. An IC50 calculation, a standard laboratory inhibiting measure, showed that TFC-723 was seven times more effective at inhibiting human tyrosinase activity than beta arbutin.

Additional studies are being conducted to compare the company's other depigmenting agent, TFC-849, against alpha arbutin, another popular commercial skin lightening agent. Stability studies are also being conducted on TFC-723 and TFC-849.

Sirona Biochem's subsidiary, TFChem, is developing skin depigmenting agents to be used as cosmetic skin lighteners. The company's goal is to develop new, effective depigmenting agents that are stable and do not release hydroquinone, a common adverse effect of many skin lighteners.

According to Global Industry Analysts, the global skin lightening market was estimated to be US$7.5 billion in 2009 and is expected to exceed US$10 billion by 2015. It is estimated approximately 15 percent of the global population invests in skin lightening products. In Japan alone, an estimated US$5.9B was spent on skin lighteners.

About Sirona Biochem Corp.

Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. For more information visit [ www.sironabiochem.com ].

About the Project.

Sirona Biochem's French subsidiary, TFChem received in November 2011 a $1.9-million grant. This project is co-financed by the European Union and Europe witnesses in Haute-Normandie with the support of European Regional Development Fund (E.R.D.F.). A consortium of partners - including TFChem, the University of Rouen (LMSM EA4312) and contract research organization Biogalenys - has been assembled to advance this project. The French government and European Union are looking to promote and initiate collaborative projects that are focused on the development of new products and services containing a high level of innovation.

We seek Safe Harbor

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.




Publication Contributing Sources